Geert-Jan Mulder MD
Managing Partner
Developing disease modifying Alkaline Phosphatase therapeutics.
AM-Pharma is a biopharmaceutical company developing a novel recombinant human alkaline phosphatase for treatments of severe inflammatory mediated diseases.
Alkaline Phosphatase plays a key role as an anti-inflammatory agent in various disease pathways. The Company’s lead program is focused on a registration trajectory in Acute Kidney Injury.
Industry
Biotech
Status
Current
Location
The Netherlands
To date, our lead candidate, ilofotase alfa, has been evaluated in approximately 1,000 patients and has established an impressive clinical record of renal protective effects. Forbion has been a long-term, visionary investor since AM-Pharma transitioned to a clinical-stage company. The team’s scientific, clinical, and commercial expertise was instrumental in the strategic redirection of our development plan for ilofotase alfa, and they continue to show their unwavering commitment to bringing promising therapeutic candidates over the finish line, even for high-risk areas such as critical care. As we are approaching enrollment completion for our Phase 2 trial in cardiac surgery-associated renal damage, the Forbion team remains focused on maximizing value for patients, as well as all other stakeholders, by enabling us to demonstrate the therapeutic impact that ilofotase alfa could bring to this area of high unmet medical need.Juliane Bernholz, Ph.D.
CEO of AM-Pharma
>1000
patients enrolled
Forbion team